MILTON, ONTARIO--(Marketwire - Jan. 3, 2012) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF)(OTCBB:SLXCF)(PINK SHEETS:SLXCF), a Canadian public company, announced today that Murray Roach has joined the company as Vice President of Sales. Mr. Roach has nearly 20 years of pharmaceutical sales and marketing experience in Canada, including most recently where he served as Vice President, Sales and Marketing for Taro Pharmaceuticals in Canada. In this capacity Mr. Roach gained an extensive experience in the dermatology market nationally in all aspects of the business.

Prior to Taro Pharmaceuticals, Mr. Roach spent 15 years at Wyeth Canada in several senior sales and marketing positions including Director of Sales, Pharmaceuticals, Director of Sales, Biopharmaceuticals and Product Manager for Effexor® (venlafaxine). Mr. Roach enjoyed many years of success at Wyeth Canada and won numerous sales and marketing awards during his career with Wyeth. He began his career with Wyeth as a sales representative in Saskatchewan and is a graduate of the University of Saskatchewan, College of Education.

About Stellar Pharmaceuticals Inc.

Stellar Pharma and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market. Stellar Pharma currently competes in the dermatology market in Canada with its promotion of Soriatane®* (acitretin).

Stellar also markets Bezalip®* SR (bezafibrate) NeoVisc® (1.0% sodium hyaluronate solution) and Uracyst® (sodium chondroitin sulfate solution 2%) in the Canadian market place and is awaiting regulatory approval for Cambia®** (diclofenac potassium for oral solution) in Canada. Additionally, NeoVisc and Uracyst are commercially available in 58 countries and are sold globally through various international partnerships. Stellar is currently in negotiations to license both NeoVisc and Uracyst in the US and other international markets.

*Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf

**Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc.

distribué par

Ce noodl a été diffusé par Stellar Pharmaceuticals Inc. et initialement mise en ligne sur le site http://www.stellarpharma.com. La version originale est disponible ici.

Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-03 16:05:44 PM et restera accessible depuis ce lien permanent.

Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité.